EAU 2019

The European Association of Urology (EAU) held its annual congress in Barcelona, Spain this month. There were presentations about partial nephrectomy, neoadjuvant treatment of renal cell carcinoma (RCC), and the management of RCC. Here are some of the more interesting RCC presentations for you to browse through: EAU 2019: The Challenging Landscape in Advanced Renal […]

read more

Hand-foot syndrome as a predictor of better outcomes in patients treated with sunitinib

A recent study, published in the journal Advances in Medicine and Medical Research, suggests that the presence of hand-foot syndrome in patients with metastatic renal cell carcinoma (RCC) after the first cycle of treatment with sunitinib predicts longer progression-free survival. Median progression-free survival was 9.8 months in those patients who did not experience hand-foot syndrome […]

read more

Phytochemicals and cancer

Phytochemicals are compounds produced by plants to give them their colour, smell or taste. They have a number of different functions, such as deterring predators or responding to tissue damage or infection. Some phytochemicals are believed to have human health benefits as a result of their antioxidant, anti-inflammatory, or antiproliferative activity, and are also thought […]

read more

Cryoablation versus partial nephrectomy for early stage renal masses

A recent study, published in the Journal of Cancer, conducted a systematic review and meta-analysis of the outcomes data for the use of cryoablation versus partial nephrectomy for early stage (T1) renal tumours. The review showed that cryoablation is linked with poorer oncologic outcomes than partial nephrectomy, but patients who underwent cryoablation had lower rates […]

read more

Syntaxin 6: A potential biomarker for papillary renal cell carcinoma

A recent study published in Scientific Reports last month has identified Syntaxin 6, a protein known to play an important role in the movement of protein and lipids within cells (intracellular trafficking), as a prognostic biomarker for patients with a type of kidney cancer called papillary renal cell carcinoma (RCC). Syntaxin 6 also holds promise […]

read more

Tivozanib included in new European guidelines for kidney cancer

Tivozanib has been included as a first-line treatment recommendation for advanced renal cell carcinoma (aRCC) in new European Society of Medical Oncology (ESMO) clinical practice guidelines for RCC, published last month. Tivozanib is recommended as a first-line treatment option for people with advanced clear cell RCC of good (favourable) risk or intermediate risk. Tivozanib is a potent selective vascular endothelial growth factor […]

read more
Showing 1 to 6 of 549 results